Modus Therapeutics Holding AB (OSTO:MODTX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Modus Therapeutics Holding AB EBITDA Margin % Related Terms
Modus Therapeutics Holding AB EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Modus Therapeutics Holding AB EBITDA Margin % Chart
OSTO:MODTX vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Modus Therapeutics Holding AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Modus Therapeutics Holding AB EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Modus Therapeutics Holding AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Modus Therapeutics Holding AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Modus Therapeutics Holding AB (OSTO:MODTX) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Modus Therapeutics Holding AB and its competitors. According to the industry distribution chart, Modus Therapeutics Holding AB ranks #999999 out of 945 companies in the Biotechnology industry.
Is Modus Therapeutics Holding AB's EBITDA Margin % too high?
Modus Therapeutics Holding AB's current EBITDA Margin % is 0.00%. Based on the distribution chart, Modus Therapeutics Holding AB ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Modus Therapeutics Holding AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Modus Therapeutics Holding AB's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Modus Therapeutics Holding AB ranks #999999 out of 945 companies for EBITDA Margin %. This places Modus Therapeutics Holding AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Modus Therapeutics Holding AB and its competitors. Modus Therapeutics Holding AB's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modus Therapeutics Holding AB stock overvalued right now?
Modus Therapeutics Holding AB (OSTO:MODTX) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Modus Therapeutics Holding AB's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Modus Therapeutics Holding AB (OSTO:MODTX), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Modus Therapeutics Holding AB Business Description
Modus Therapeutics Holding AB is a Swedish biotechnology company developing its patented polysaccharide, sevuparin, as a potential treatment for unmet medical needs. Its research focuses on conditions involving severe systemic inflammation, including sepsis and septic shock, severe malaria, and other related disorders, as well as anemia associated with chronic inflammatory conditions such as kidney disease.
30GF Score
Get the complete analysis for OSTO:MODTX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MODTX has been successfully added to your 
